Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 46 | 2023 | 763 | 9.990 |
Why?
|
Myelodysplastic Syndromes | 31 | 2023 | 346 | 6.480 |
Why?
|
Myeloproliferative Disorders | 20 | 2023 | 110 | 6.100 |
Why?
|
Leukemia | 21 | 2023 | 320 | 5.690 |
Why?
|
Bone Marrow | 40 | 2023 | 435 | 5.490 |
Why?
|
Immunophenotyping | 54 | 2023 | 211 | 3.510 |
Why?
|
Leukemia, Myeloid | 19 | 2016 | 249 | 3.320 |
Why?
|
Chromosome Aberrations | 25 | 2023 | 387 | 3.060 |
Why?
|
Translocation, Genetic | 26 | 2016 | 265 | 3.020 |
Why?
|
Lymphoma, T-Cell | 15 | 2022 | 48 | 2.880 |
Why?
|
Mutation | 39 | 2023 | 3967 | 2.650 |
Why?
|
World Health Organization | 15 | 2022 | 103 | 2.330 |
Why?
|
Lymphoma, Follicular | 15 | 2016 | 70 | 2.230 |
Why?
|
Lymphoma, B-Cell | 21 | 2022 | 103 | 2.200 |
Why?
|
Hematologic Neoplasms | 15 | 2022 | 329 | 2.130 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2022 | 375 | 2.080 |
Why?
|
Biomarkers, Tumor | 37 | 2017 | 1464 | 2.030 |
Why?
|
Lymphoma | 14 | 2022 | 262 | 1.980 |
Why?
|
Pancytopenia | 4 | 2016 | 23 | 1.950 |
Why?
|
Neoplasm Proteins | 12 | 2020 | 532 | 1.930 |
Why?
|
Humans | 261 | 2023 | 86601 | 1.920 |
Why?
|
Leukemia, Erythroblastic, Acute | 4 | 2022 | 29 | 1.760 |
Why?
|
Immunohistochemistry | 53 | 2022 | 1753 | 1.620 |
Why?
|
Bone Marrow Examination | 10 | 2020 | 48 | 1.590 |
Why?
|
Herpesvirus 4, Human | 12 | 2015 | 114 | 1.590 |
Why?
|
Leukemia, Biphenotypic, Acute | 3 | 2022 | 4 | 1.570 |
Why?
|
Middle Aged | 120 | 2021 | 25017 | 1.510 |
Why?
|
Prognosis | 38 | 2023 | 3674 | 1.500 |
Why?
|
Male | 149 | 2021 | 40956 | 1.450 |
Why?
|
Tumor Suppressor Protein p53 | 7 | 2023 | 381 | 1.430 |
Why?
|
Antigens, CD | 28 | 2014 | 458 | 1.420 |
Why?
|
Aged, 80 and over | 58 | 2021 | 6501 | 1.370 |
Why?
|
Acute Disease | 22 | 2023 | 826 | 1.370 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 5 | 2020 | 21 | 1.360 |
Why?
|
Lymphoma, T-Cell, Peripheral | 6 | 2022 | 27 | 1.360 |
Why?
|
DNA Mutational Analysis | 14 | 2020 | 526 | 1.340 |
Why?
|
Lymphoma, Non-Hodgkin | 12 | 2015 | 261 | 1.340 |
Why?
|
Hodgkin Disease | 11 | 2020 | 177 | 1.330 |
Why?
|
Aged | 91 | 2021 | 18402 | 1.320 |
Why?
|
Female | 138 | 2021 | 44507 | 1.300 |
Why?
|
Lymph Nodes | 18 | 2015 | 530 | 1.280 |
Why?
|
Adult | 107 | 2021 | 25640 | 1.270 |
Why?
|
Polymerase Chain Reaction | 25 | 2015 | 927 | 1.260 |
Why?
|
Karyotyping | 18 | 2016 | 250 | 1.250 |
Why?
|
T-Lymphocytes | 11 | 2019 | 1195 | 1.190 |
Why?
|
Pathology, Clinical | 2 | 2017 | 33 | 1.190 |
Why?
|
Proto-Oncogene Proteins c-kit | 6 | 2015 | 79 | 1.110 |
Why?
|
Gene Rearrangement | 11 | 2021 | 170 | 1.080 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 53 | 1.050 |
Why?
|
Child, Preschool | 28 | 2021 | 3611 | 1.050 |
Why?
|
Adolescent | 50 | 2021 | 8979 | 1.030 |
Why?
|
Karyotype | 6 | 2023 | 33 | 1.030 |
Why?
|
Splenic Neoplasms | 6 | 2010 | 16 | 1.000 |
Why?
|
Oncogene Proteins, Fusion | 8 | 2018 | 128 | 0.980 |
Why?
|
Proto-Oncogene Proteins | 11 | 2019 | 645 | 0.970 |
Why?
|
Chromosomes, Human, Pair 21 | 6 | 2015 | 54 | 0.960 |
Why?
|
Child | 36 | 2022 | 6926 | 0.950 |
Why?
|
Pathology | 3 | 2020 | 30 | 0.930 |
Why?
|
STAT3 Transcription Factor | 2 | 2014 | 78 | 0.930 |
Why?
|
DNA-Binding Proteins | 11 | 2019 | 1208 | 0.920 |
Why?
|
Bone Marrow Neoplasms | 5 | 2018 | 17 | 0.880 |
Why?
|
Leukemia, Large Granular Lymphocytic | 2 | 2013 | 2 | 0.870 |
Why?
|
Immunoglobulin Heavy Chains | 10 | 2014 | 131 | 0.850 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2020 | 173 | 0.840 |
Why?
|
Flow Cytometry | 21 | 2017 | 679 | 0.830 |
Why?
|
Diagnosis, Differential | 27 | 2019 | 1565 | 0.830 |
Why?
|
Neoplasms | 10 | 2023 | 2897 | 0.810 |
Why?
|
Ki-1 Antigen | 4 | 2013 | 17 | 0.810 |
Why?
|
Bone Marrow Cells | 8 | 2015 | 253 | 0.800 |
Why?
|
Splicing Factor U2AF | 2 | 2018 | 5 | 0.790 |
Why?
|
Antigens, CD34 | 8 | 2014 | 158 | 0.780 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 4 | 2013 | 37 | 0.760 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 9 | 2022 | 189 | 0.760 |
Why?
|
Young Adult | 27 | 2021 | 5974 | 0.760 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2018 | 137 | 0.750 |
Why?
|
In Situ Hybridization, Fluorescence | 22 | 2017 | 348 | 0.730 |
Why?
|
Janus Kinase 2 | 7 | 2023 | 57 | 0.720 |
Why?
|
B-Lymphocytes | 13 | 2017 | 724 | 0.710 |
Why?
|
Spleen | 2 | 2020 | 430 | 0.700 |
Why?
|
Phenotype | 16 | 2022 | 2377 | 0.690 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 1 | 2019 | 55 | 0.690 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 2 | 2008 | 8 | 0.670 |
Why?
|
Nuclear Proteins | 10 | 2023 | 696 | 0.660 |
Why?
|
Infant | 15 | 2018 | 3045 | 0.660 |
Why?
|
Skin Neoplasms | 11 | 2019 | 541 | 0.660 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2018 | 36 | 0.660 |
Why?
|
fms-Like Tyrosine Kinase 3 | 7 | 2022 | 127 | 0.650 |
Why?
|
Disease-Free Survival | 11 | 2020 | 1204 | 0.650 |
Why?
|
Mastocytosis | 4 | 2017 | 13 | 0.650 |
Why?
|
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 3 | 2010 | 14 | 0.640 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 4 | 2011 | 102 | 0.630 |
Why?
|
Killer Cells, Natural | 5 | 2021 | 267 | 0.620 |
Why?
|
Neoplasms, Second Primary | 6 | 2022 | 252 | 0.620 |
Why?
|
Mastocytosis, Systemic | 5 | 2023 | 11 | 0.600 |
Why?
|
Retrospective Studies | 33 | 2023 | 8475 | 0.600 |
Why?
|
Biopsy | 18 | 2020 | 1161 | 0.600 |
Why?
|
Sarcoma | 8 | 2005 | 211 | 0.580 |
Why?
|
Consensus | 6 | 2023 | 335 | 0.580 |
Why?
|
DNA Methylation | 4 | 2015 | 628 | 0.570 |
Why?
|
Myelodysplastic-Myeloproliferative Diseases | 4 | 2022 | 9 | 0.550 |
Why?
|
Burkitt Lymphoma | 6 | 2003 | 31 | 0.550 |
Why?
|
Genes, T-Cell Receptor gamma | 2 | 2008 | 3 | 0.550 |
Why?
|
Hematology | 2 | 2018 | 29 | 0.550 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 8 | 2016 | 151 | 0.550 |
Why?
|
Chromosomes, Human, Pair 5 | 5 | 2023 | 109 | 0.550 |
Why?
|
Neuroblastoma | 2 | 2009 | 374 | 0.530 |
Why?
|
Granulocyte Precursor Cells | 2 | 2014 | 7 | 0.530 |
Why?
|
Hypereosinophilic Syndrome | 3 | 2023 | 5 | 0.530 |
Why?
|
Epigenesis, Genetic | 2 | 2019 | 479 | 0.520 |
Why?
|
Neprilysin | 6 | 2003 | 42 | 0.510 |
Why?
|
Abnormal Karyotype | 4 | 2023 | 8 | 0.510 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2019 | 456 | 0.510 |
Why?
|
Lymphoma, AIDS-Related | 3 | 2002 | 6 | 0.510 |
Why?
|
Granuloma, Plasma Cell | 3 | 2001 | 9 | 0.510 |
Why?
|
Bone Marrow Transplantation | 3 | 2014 | 286 | 0.510 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 8 | 0.510 |
Why?
|
Monosomy | 1 | 2014 | 12 | 0.500 |
Why?
|
Tumor Virus Infections | 4 | 2015 | 81 | 0.490 |
Why?
|
Cell Lineage | 7 | 2022 | 273 | 0.480 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2008 | 302 | 0.480 |
Why?
|
Clone Cells | 9 | 2013 | 213 | 0.480 |
Why?
|
Antigens, Neoplasm | 9 | 2001 | 325 | 0.470 |
Why?
|
Receptors, Antigen, B-Cell | 7 | 2021 | 113 | 0.470 |
Why?
|
Kaplan-Meier Estimate | 7 | 2017 | 860 | 0.470 |
Why?
|
Liver Neoplasms | 4 | 2016 | 735 | 0.460 |
Why?
|
Cadherins | 1 | 2014 | 151 | 0.460 |
Why?
|
Bone Marrow Diseases | 2 | 2013 | 40 | 0.460 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2006 | 100 | 0.450 |
Why?
|
Polycythemia Vera | 2 | 2023 | 23 | 0.450 |
Why?
|
Neoplasms, Multiple Primary | 5 | 2015 | 100 | 0.450 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 6 | 2007 | 136 | 0.440 |
Why?
|
Receptors, CXCR4 | 1 | 2013 | 44 | 0.440 |
Why?
|
Epstein-Barr Virus Infections | 3 | 2015 | 50 | 0.430 |
Why?
|
Arachidonate 12-Lipoxygenase | 1 | 2012 | 23 | 0.430 |
Why?
|
Glutathione Transferase | 1 | 2012 | 111 | 0.430 |
Why?
|
Paraffin Embedding | 12 | 2010 | 78 | 0.420 |
Why?
|
Leukemia, Promyelocytic, Acute | 5 | 2017 | 49 | 0.420 |
Why?
|
Mast Cells | 4 | 2015 | 92 | 0.410 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 581 | 0.410 |
Why?
|
Dendritic Cells, Follicular | 3 | 2008 | 20 | 0.410 |
Why?
|
Genetic Predisposition to Disease | 7 | 2020 | 2270 | 0.390 |
Why?
|
Herpesviridae Infections | 3 | 1996 | 46 | 0.390 |
Why?
|
Hematopoietic Stem Cell Transplantation | 7 | 2020 | 878 | 0.390 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2011 | 100 | 0.390 |
Why?
|
Peroxidase | 3 | 2001 | 51 | 0.390 |
Why?
|
Abdominal Neoplasms | 2 | 2001 | 39 | 0.380 |
Why?
|
Multiple Myeloma | 3 | 2022 | 307 | 0.380 |
Why?
|
Herpesvirus 8, Human | 2 | 2002 | 11 | 0.380 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 4 | 2006 | 20 | 0.380 |
Why?
|
Chromosomes, Human, Pair 3 | 4 | 2014 | 54 | 0.370 |
Why?
|
Nose Neoplasms | 3 | 2002 | 31 | 0.360 |
Why?
|
DNA, Neoplasm | 11 | 2013 | 265 | 0.360 |
Why?
|
CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 5 | 0.360 |
Why?
|
Blood Transfusion | 1 | 2010 | 157 | 0.350 |
Why?
|
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 3 | 2021 | 3 | 0.350 |
Why?
|
Antigens, CD20 | 8 | 2013 | 36 | 0.350 |
Why?
|
Survival Analysis | 7 | 2013 | 1538 | 0.350 |
Why?
|
Chromosome Inversion | 4 | 2014 | 47 | 0.340 |
Why?
|
Quality Assurance, Health Care | 1 | 2010 | 220 | 0.340 |
Why?
|
Dioxygenases | 3 | 2019 | 74 | 0.330 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 5 | 2016 | 22 | 0.330 |
Why?
|
Microtubule-Associated Proteins | 1 | 2009 | 176 | 0.330 |
Why?
|
Chromosomes, Human, Pair 8 | 4 | 2013 | 85 | 0.330 |
Why?
|
Blast Crisis | 3 | 2020 | 33 | 0.320 |
Why?
|
Cytogenetic Analysis | 4 | 2020 | 71 | 0.320 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 2 | 2015 | 52 | 0.320 |
Why?
|
Clostridium perfringens | 1 | 2007 | 7 | 0.320 |
Why?
|
RNA Splicing Factors | 2 | 2020 | 27 | 0.320 |
Why?
|
Germinal Center | 3 | 2015 | 55 | 0.320 |
Why?
|
Skin Diseases | 3 | 2010 | 166 | 0.320 |
Why?
|
Leukemia, B-Cell | 4 | 2010 | 23 | 0.310 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 4 | 2005 | 32 | 0.310 |
Why?
|
Neoplasm Staging | 6 | 2015 | 1937 | 0.310 |
Why?
|
Hemolysis | 1 | 2007 | 61 | 0.310 |
Why?
|
Histiocytic Sarcoma | 3 | 2016 | 8 | 0.310 |
Why?
|
Chromosome Breakage | 1 | 2007 | 17 | 0.310 |
Why?
|
Chromosomes, Human, Pair 14 | 4 | 2015 | 49 | 0.310 |
Why?
|
In Situ Hybridization | 7 | 2015 | 307 | 0.310 |
Why?
|
California | 5 | 2018 | 138 | 0.310 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 9 | 2010 | 879 | 0.300 |
Why?
|
Disease Models, Animal | 1 | 2014 | 2232 | 0.300 |
Why?
|
Lymphoproliferative Disorders | 4 | 2002 | 107 | 0.300 |
Why?
|
Lymphocyte Activation | 2 | 2021 | 728 | 0.300 |
Why?
|
Eosinophilia | 3 | 2017 | 84 | 0.300 |
Why?
|
beta Catenin | 1 | 2009 | 251 | 0.300 |
Why?
|
Vimentin | 6 | 2002 | 44 | 0.290 |
Why?
|
Hemangioendothelioma | 1 | 2006 | 9 | 0.290 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2006 | 48 | 0.290 |
Why?
|
Remission Induction | 5 | 2019 | 722 | 0.290 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 2357 | 0.290 |
Why?
|
Phosphoproteins | 2 | 2020 | 254 | 0.290 |
Why?
|
Quality Improvement | 1 | 2010 | 428 | 0.280 |
Why?
|
Dendritic Cell Sarcoma, Follicular | 3 | 2012 | 3 | 0.280 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2006 | 43 | 0.280 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2006 | 79 | 0.280 |
Why?
|
Philadelphia Chromosome | 1 | 2006 | 38 | 0.280 |
Why?
|
Survival Rate | 6 | 2020 | 1860 | 0.270 |
Why?
|
Cell Proliferation | 6 | 2019 | 1578 | 0.270 |
Why?
|
Medical Records | 3 | 2015 | 119 | 0.270 |
Why?
|
Biomarkers | 5 | 2022 | 1718 | 0.270 |
Why?
|
Clostridium Infections | 1 | 2007 | 125 | 0.270 |
Why?
|
Neoplastic Stem Cells | 4 | 2015 | 143 | 0.270 |
Why?
|
Chromosomes, Human, Pair 11 | 2 | 2003 | 106 | 0.270 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 2005 | 3 | 0.260 |
Why?
|
Recombinant Fusion Proteins | 2 | 2006 | 557 | 0.260 |
Why?
|
Transcription Factors | 6 | 2023 | 1565 | 0.260 |
Why?
|
Keratins | 3 | 2000 | 63 | 0.260 |
Why?
|
Mycosis Fungoides | 3 | 2011 | 23 | 0.260 |
Why?
|
Leukemia, T-Cell | 3 | 2010 | 17 | 0.260 |
Why?
|
Practice Guidelines as Topic | 5 | 2019 | 1034 | 0.260 |
Why?
|
Sensitivity and Specificity | 9 | 2017 | 1990 | 0.260 |
Why?
|
Primary Myelofibrosis | 2 | 2023 | 56 | 0.260 |
Why?
|
Castleman Disease | 2 | 2012 | 13 | 0.250 |
Why?
|
Disseminated Intravascular Coagulation | 2 | 2017 | 27 | 0.250 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2014 | 2436 | 0.250 |
Why?
|
Genes, Immunoglobulin | 4 | 2013 | 111 | 0.240 |
Why?
|
Whole-Body Irradiation | 5 | 2020 | 63 | 0.240 |
Why?
|
Sarcoma, Endometrial Stromal | 2 | 2001 | 8 | 0.230 |
Why?
|
Predictive Value of Tests | 5 | 2017 | 1673 | 0.230 |
Why?
|
Telomerase | 1 | 2003 | 55 | 0.230 |
Why?
|
Chromosomes, Human, Pair 18 | 3 | 2015 | 42 | 0.230 |
Why?
|
Reproducibility of Results | 5 | 2017 | 2705 | 0.230 |
Why?
|
Polycythemia | 1 | 2023 | 8 | 0.230 |
Why?
|
Sarcoma, Myeloid | 1 | 2023 | 15 | 0.230 |
Why?
|
Antibodies, Monoclonal | 5 | 2007 | 1376 | 0.230 |
Why?
|
Sarcoma, Kaposi | 1 | 2002 | 19 | 0.220 |
Why?
|
Plasmacytoma | 1 | 2022 | 34 | 0.220 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2002 | 3 | 0.220 |
Why?
|
Pleural Effusion, Malignant | 1 | 2002 | 15 | 0.220 |
Why?
|
Glucose Transporter Type 1 | 1 | 2022 | 20 | 0.220 |
Why?
|
Synaptophysin | 3 | 2009 | 11 | 0.220 |
Why?
|
Chromosomes, Human, Pair 9 | 3 | 2018 | 86 | 0.220 |
Why?
|
Pleural Neoplasms | 1 | 2004 | 188 | 0.210 |
Why?
|
Cytoplasm | 4 | 2009 | 281 | 0.210 |
Why?
|
Intestinal Neoplasms | 1 | 2002 | 56 | 0.210 |
Why?
|
Isochromosomes | 1 | 2021 | 1 | 0.210 |
Why?
|
Sialoglycoproteins | 2 | 1999 | 31 | 0.210 |
Why?
|
Breast Neoplasms | 4 | 2008 | 2887 | 0.210 |
Why?
|
Cytarabine | 3 | 2020 | 218 | 0.210 |
Why?
|
Transplantation Conditioning | 3 | 2020 | 373 | 0.210 |
Why?
|
Immunoblastic Lymphadenopathy | 2 | 2012 | 5 | 0.210 |
Why?
|
Biopsy, Needle | 4 | 2015 | 235 | 0.210 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2022 | 106 | 0.200 |
Why?
|
Terminology as Topic | 2 | 2009 | 217 | 0.200 |
Why?
|
Daunorubicin | 2 | 2020 | 78 | 0.200 |
Why?
|
Mesothelioma | 1 | 2004 | 311 | 0.200 |
Why?
|
Monocytes | 2 | 2017 | 214 | 0.200 |
Why?
|
PubMed | 1 | 2020 | 12 | 0.200 |
Why?
|
Chromosomes, Human, Pair 17 | 3 | 2005 | 110 | 0.190 |
Why?
|
Blood Cells | 1 | 2020 | 33 | 0.190 |
Why?
|
Receptors, Thrombopoietin | 1 | 2020 | 4 | 0.190 |
Why?
|
Calreticulin | 1 | 2020 | 13 | 0.190 |
Why?
|
Endometrial Neoplasms | 2 | 2001 | 193 | 0.190 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2000 | 24 | 0.190 |
Why?
|
CD79 Antigens | 7 | 2013 | 17 | 0.190 |
Why?
|
Photopheresis | 1 | 2020 | 12 | 0.190 |
Why?
|
Plasma Cells | 3 | 2006 | 80 | 0.190 |
Why?
|
Monocyte-Macrophage Precursor Cells | 1 | 2020 | 4 | 0.190 |
Why?
|
Aminopyridines | 1 | 2020 | 38 | 0.190 |
Why?
|
Core Binding Factors | 1 | 2020 | 12 | 0.190 |
Why?
|
Intestine, Small | 1 | 2002 | 303 | 0.190 |
Why?
|
Genetic Markers | 3 | 2016 | 476 | 0.190 |
Why?
|
Triazines | 1 | 2020 | 53 | 0.190 |
Why?
|
PAX5 Transcription Factor | 2 | 2013 | 32 | 0.190 |
Why?
|
Immunoenzyme Techniques | 8 | 2009 | 303 | 0.190 |
Why?
|
Follow-Up Studies | 9 | 2014 | 3636 | 0.180 |
Why?
|
Genomics | 2 | 2022 | 720 | 0.180 |
Why?
|
Infant, Newborn | 4 | 2016 | 2378 | 0.180 |
Why?
|
Carcinoma, Lobular | 1 | 2000 | 80 | 0.180 |
Why?
|
Panniculitis | 1 | 2019 | 8 | 0.180 |
Why?
|
Hematopoietic Stem Cells | 3 | 2013 | 292 | 0.180 |
Why?
|
Precancerous Conditions | 2 | 2019 | 196 | 0.180 |
Why?
|
Clinical Protocols | 2 | 2010 | 156 | 0.180 |
Why?
|
Sequence Analysis, DNA | 2 | 2009 | 853 | 0.180 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2002 | 199 | 0.180 |
Why?
|
Biological Products | 1 | 2021 | 143 | 0.180 |
Why?
|
Giant Cells | 1 | 1999 | 19 | 0.180 |
Why?
|
Adenocarcinoma | 3 | 2012 | 1169 | 0.170 |
Why?
|
Immunoglobulin Light Chains | 2 | 2015 | 86 | 0.170 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2001 | 372 | 0.170 |
Why?
|
Bone Neoplasms | 1 | 2002 | 322 | 0.170 |
Why?
|
Consolidation Chemotherapy | 1 | 2019 | 22 | 0.170 |
Why?
|
Cohort Studies | 4 | 2023 | 2767 | 0.170 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 5 | 2002 | 20 | 0.170 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 1999 | 59 | 0.170 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2000 | 118 | 0.170 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2019 | 83 | 0.170 |
Why?
|
RNA, Messenger | 3 | 2009 | 1981 | 0.170 |
Why?
|
Down Syndrome | 2 | 2016 | 53 | 0.170 |
Why?
|
Proto-Oncogene Proteins A-raf | 1 | 2018 | 1 | 0.170 |
Why?
|
Fusion Proteins, bcr-abl | 2 | 2018 | 107 | 0.170 |
Why?
|
Disease Progression | 8 | 2018 | 1531 | 0.170 |
Why?
|
Tissue Array Analysis | 4 | 2015 | 124 | 0.170 |
Why?
|
Leukemia, Mast-Cell | 2 | 2010 | 5 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 4 | 2007 | 43 | 0.160 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2018 | 19 | 0.160 |
Why?
|
Polymorphism, Genetic | 1 | 2002 | 819 | 0.160 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2008 | 153 | 0.160 |
Why?
|
Multi-Institutional Systems | 1 | 2018 | 4 | 0.160 |
Why?
|
ras Proteins | 3 | 2018 | 128 | 0.160 |
Why?
|
Erythroid Cells | 1 | 2018 | 14 | 0.160 |
Why?
|
Skin | 2 | 2013 | 554 | 0.160 |
Why?
|
Mutation Rate | 1 | 2018 | 48 | 0.160 |
Why?
|
Mutation, Missense | 1 | 2019 | 276 | 0.160 |
Why?
|
Pathology, Surgical | 2 | 2010 | 12 | 0.160 |
Why?
|
Decalcification Technique | 1 | 1997 | 2 | 0.160 |
Why?
|
Graft vs Host Disease | 1 | 2020 | 365 | 0.160 |
Why?
|
Chromogranins | 3 | 2009 | 11 | 0.160 |
Why?
|
Leukocyte Common Antigens | 3 | 2015 | 46 | 0.160 |
Why?
|
Liver Transplantation | 2 | 2008 | 1267 | 0.160 |
Why?
|
Kidney Neoplasms | 2 | 2001 | 621 | 0.160 |
Why?
|
Proteins | 1 | 2003 | 777 | 0.160 |
Why?
|
Neoplasms, Vascular Tissue | 1 | 1997 | 3 | 0.160 |
Why?
|
History, 21st Century | 1 | 2018 | 175 | 0.150 |
Why?
|
Basophils | 1 | 1997 | 25 | 0.150 |
Why?
|
Chelating Agents | 1 | 1997 | 69 | 0.150 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2017 | 28 | 0.150 |
Why?
|
Specimen Handling | 2 | 2010 | 98 | 0.150 |
Why?
|
Lymphangioma | 1 | 1997 | 15 | 0.150 |
Why?
|
Colonic Neoplasms | 2 | 2012 | 556 | 0.150 |
Why?
|
Histones | 1 | 2019 | 311 | 0.150 |
Why?
|
Genotype | 4 | 2019 | 1850 | 0.150 |
Why?
|
Splenic Diseases | 1 | 1997 | 16 | 0.150 |
Why?
|
DNA | 3 | 2005 | 1294 | 0.150 |
Why?
|
Lymphocyte Subsets | 1 | 2017 | 64 | 0.150 |
Why?
|
Diagnostic Errors | 4 | 2010 | 160 | 0.150 |
Why?
|
Antigens, Surface | 1 | 1997 | 101 | 0.150 |
Why?
|
Blood Coagulation | 1 | 2017 | 91 | 0.150 |
Why?
|
Carcinoma, Renal Cell | 2 | 2001 | 426 | 0.140 |
Why?
|
Cell Count | 2 | 2014 | 195 | 0.140 |
Why?
|
Aneuploidy | 2 | 1997 | 55 | 0.140 |
Why?
|
Stomach Neoplasms | 2 | 2015 | 266 | 0.140 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 1996 | 25 | 0.140 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 1996 | 85 | 0.140 |
Why?
|
Genes, Neoplasm | 1 | 2016 | 37 | 0.140 |
Why?
|
Age Factors | 3 | 2017 | 1849 | 0.140 |
Why?
|
Muscle Neoplasms | 1 | 2016 | 18 | 0.140 |
Why?
|
Cytogenetics | 2 | 2015 | 27 | 0.140 |
Why?
|
Antigens, CD19 | 3 | 2013 | 39 | 0.140 |
Why?
|
Cysts | 1 | 1997 | 104 | 0.140 |
Why?
|
Immunoglobulins | 2 | 2013 | 148 | 0.140 |
Why?
|
RNA, Neoplasm | 3 | 2003 | 87 | 0.140 |
Why?
|
Histiocytosis | 1 | 2015 | 4 | 0.140 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2015 | 15 | 0.140 |
Why?
|
Certification | 1 | 1996 | 58 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2015 | 25 | 0.140 |
Why?
|
Myeloid Cells | 1 | 2016 | 98 | 0.140 |
Why?
|
Carcinoma, Signet Ring Cell | 2 | 2012 | 8 | 0.130 |
Why?
|
Neuroendocrine Tumors | 1 | 1997 | 105 | 0.130 |
Why?
|
Molecular Biology | 1 | 1996 | 89 | 0.130 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2015 | 19 | 0.130 |
Why?
|
False Positive Reactions | 2 | 2009 | 216 | 0.130 |
Why?
|
Pyridazines | 1 | 2015 | 22 | 0.130 |
Why?
|
Mediastinal Neoplasms | 1 | 2015 | 46 | 0.130 |
Why?
|
Comparative Genomic Hybridization | 1 | 2015 | 39 | 0.130 |
Why?
|
Chromosome Deletion | 4 | 2023 | 229 | 0.130 |
Why?
|
Proportional Hazards Models | 2 | 2014 | 857 | 0.130 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 12 | 0.130 |
Why?
|
Microsatellite Instability | 2 | 2012 | 43 | 0.130 |
Why?
|
Repressor Proteins | 2 | 2017 | 403 | 0.130 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2015 | 1 | 0.130 |
Why?
|
Receptors, Complement 3d | 1 | 2015 | 14 | 0.130 |
Why?
|
Anemia, Sideroblastic | 1 | 2015 | 6 | 0.130 |
Why?
|
Immunotherapy | 1 | 2020 | 629 | 0.130 |
Why?
|
Fatal Outcome | 4 | 2010 | 293 | 0.130 |
Why?
|
LIM Domain Proteins | 1 | 2015 | 25 | 0.130 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2015 | 689 | 0.130 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 44 | 0.130 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 38 | 0.130 |
Why?
|
Pseudolymphoma | 1 | 2014 | 9 | 0.130 |
Why?
|
Immunoglobulin M | 1 | 2015 | 154 | 0.130 |
Why?
|
Ileal Diseases | 1 | 2014 | 25 | 0.130 |
Why?
|
CD3 Complex | 3 | 2000 | 135 | 0.120 |
Why?
|
Risk | 2 | 2013 | 674 | 0.120 |
Why?
|
Antigen-Presenting Cells | 1 | 2015 | 139 | 0.120 |
Why?
|
Imidazoles | 1 | 2015 | 162 | 0.120 |
Why?
|
Endosonography | 1 | 2015 | 96 | 0.120 |
Why?
|
Erythroblasts | 1 | 2014 | 25 | 0.120 |
Why?
|
Blotting, Southern | 4 | 2002 | 129 | 0.120 |
Why?
|
Cloning, Molecular | 2 | 2006 | 646 | 0.120 |
Why?
|
Octamer Transcription Factor-2 | 1 | 2013 | 1 | 0.120 |
Why?
|
Agar | 1 | 1993 | 8 | 0.120 |
Why?
|
Histological Techniques | 1 | 1993 | 35 | 0.120 |
Why?
|
Carcinoma | 3 | 2005 | 436 | 0.120 |
Why?
|
Neoplasm Metastasis | 2 | 2009 | 1056 | 0.120 |
Why?
|
Gene Deletion | 1 | 2015 | 329 | 0.120 |
Why?
|
Neutropenia | 2 | 2011 | 215 | 0.120 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 2426 | 0.120 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 2 | 2013 | 34 | 0.120 |
Why?
|
Dendritic Cells | 2 | 2012 | 425 | 0.110 |
Why?
|
United States | 7 | 2017 | 6665 | 0.110 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2013 | 5 | 0.110 |
Why?
|
DNA Nucleotidylexotransferase | 1 | 2012 | 11 | 0.110 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2015 | 302 | 0.110 |
Why?
|
Anemia, Aplastic | 1 | 2013 | 30 | 0.110 |
Why?
|
AIDS-Related Complex | 1 | 1992 | 1 | 0.110 |
Why?
|
Sezary Syndrome | 2 | 2005 | 8 | 0.110 |
Why?
|
Frizzled Receptors | 1 | 2012 | 15 | 0.110 |
Why?
|
Adenoma | 2 | 2012 | 235 | 0.110 |
Why?
|
Treatment Outcome | 8 | 2014 | 7988 | 0.110 |
Why?
|
Antibody Specificity | 3 | 1998 | 129 | 0.110 |
Why?
|
Combined Modality Therapy | 4 | 2009 | 1685 | 0.110 |
Why?
|
Soft Tissue Neoplasms | 3 | 1999 | 126 | 0.110 |
Why?
|
Immunoglobulin kappa-Chains | 2 | 2009 | 96 | 0.110 |
Why?
|
Lymphocyte Count | 2 | 2017 | 94 | 0.100 |
Why?
|
Cells | 1 | 1992 | 32 | 0.100 |
Why?
|
Melanoma | 3 | 2002 | 454 | 0.100 |
Why?
|
Gene Expression | 2 | 2015 | 1284 | 0.100 |
Why?
|
Ploidies | 1 | 1991 | 40 | 0.100 |
Why?
|
CD56 Antigen | 2 | 2021 | 18 | 0.100 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2011 | 17 | 0.100 |
Why?
|
Seminal Vesicles | 1 | 1991 | 39 | 0.100 |
Why?
|
Lichen Planus | 1 | 2011 | 10 | 0.100 |
Why?
|
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2011 | 17 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2023 | 154 | 0.100 |
Why?
|
Antigens, Differentiation | 2 | 1993 | 141 | 0.100 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2011 | 118 | 0.100 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2011 | 28 | 0.100 |
Why?
|
RNA, Viral | 3 | 2000 | 327 | 0.100 |
Why?
|
Gene Frequency | 2 | 2023 | 677 | 0.100 |
Why?
|
Vaginal Neoplasms | 1 | 2011 | 83 | 0.100 |
Why?
|
Dacarbazine | 1 | 2011 | 102 | 0.100 |
Why?
|
Cell Division | 3 | 2003 | 696 | 0.100 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2011 | 138 | 0.100 |
Why?
|
Blood Group Incompatibility | 1 | 2010 | 18 | 0.100 |
Why?
|
HLA-DR Antigens | 3 | 2009 | 61 | 0.100 |
Why?
|
Chromosome Disorders | 4 | 1998 | 114 | 0.100 |
Why?
|
Trans-Activators | 1 | 2013 | 429 | 0.100 |
Why?
|
Stromal Cells | 1 | 2011 | 143 | 0.090 |
Why?
|
Splenectomy | 2 | 2010 | 82 | 0.090 |
Why?
|
Autoimmune Diseases | 1 | 2013 | 241 | 0.090 |
Why?
|
Staining and Labeling | 2 | 2010 | 165 | 0.090 |
Why?
|
Colonic Polyps | 1 | 2011 | 126 | 0.090 |
Why?
|
Immune System | 1 | 2011 | 93 | 0.090 |
Why?
|
Orbital Neoplasms | 1 | 2010 | 17 | 0.090 |
Why?
|
ABO Blood-Group System | 1 | 2010 | 62 | 0.090 |
Why?
|
Lymphadenitis | 1 | 2010 | 6 | 0.090 |
Why?
|
Genes, T-Cell Receptor | 1 | 2010 | 10 | 0.090 |
Why?
|
Formaldehyde | 2 | 2002 | 52 | 0.090 |
Why?
|
Cell Cycle Proteins | 2 | 2003 | 388 | 0.090 |
Why?
|
Antibodies | 2 | 2010 | 350 | 0.090 |
Why?
|
Cytological Techniques | 1 | 2009 | 30 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2013 | 326 | 0.090 |
Why?
|
Orbit | 1 | 2010 | 37 | 0.090 |
Why?
|
Cell Differentiation | 2 | 2014 | 1458 | 0.090 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2010 | 35 | 0.090 |
Why?
|
Trisomy | 3 | 2003 | 55 | 0.090 |
Why?
|
Frozen Sections | 4 | 2002 | 48 | 0.090 |
Why?
|
Lymphoid Enhancer-Binding Factor 1 | 1 | 2009 | 12 | 0.090 |
Why?
|
Pyrimidines | 2 | 2021 | 370 | 0.090 |
Why?
|
Lymphocytes | 3 | 1997 | 464 | 0.090 |
Why?
|
Surveys and Questionnaires | 1 | 2017 | 2501 | 0.090 |
Why?
|
Interphase | 2 | 2005 | 34 | 0.090 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2010 | 199 | 0.080 |
Why?
|
Hematoxylin | 1 | 2008 | 6 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 1996 | 1052 | 0.080 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2008 | 10 | 0.080 |
Why?
|
Prostatic Neoplasms | 2 | 1997 | 1720 | 0.080 |
Why?
|
Carcinoma, Bronchogenic | 1 | 2008 | 30 | 0.080 |
Why?
|
Leukosialin | 2 | 1999 | 16 | 0.080 |
Why?
|
Colon | 1 | 2011 | 496 | 0.080 |
Why?
|
Cryoglobulinemia | 1 | 2007 | 6 | 0.080 |
Why?
|
Liver Failure, Acute | 1 | 2008 | 38 | 0.080 |
Why?
|
Gene Amplification | 2 | 2015 | 131 | 0.080 |
Why?
|
Enzyme Inhibitors | 2 | 2018 | 639 | 0.080 |
Why?
|
DNA Probes | 2 | 2005 | 77 | 0.080 |
Why?
|
Animals | 5 | 2014 | 26581 | 0.080 |
Why?
|
Leukemia, Plasma Cell | 1 | 2006 | 1 | 0.070 |
Why?
|
Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2006 | 3 | 0.070 |
Why?
|
Lymphoma, Large-Cell, Immunoblastic | 2 | 1997 | 3 | 0.070 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2006 | 8 | 0.070 |
Why?
|
Zinc Fingers | 1 | 2006 | 56 | 0.070 |
Why?
|
src Homology Domains | 1 | 2006 | 44 | 0.070 |
Why?
|
Epithelium | 2 | 1998 | 319 | 0.070 |
Why?
|
Phosphopyruvate Hydratase | 2 | 1997 | 39 | 0.070 |
Why?
|
Core Binding Factor beta Subunit | 1 | 2006 | 2 | 0.070 |
Why?
|
Intestinal Mucosa | 1 | 2011 | 797 | 0.070 |
Why?
|
Blood Cell Count | 1 | 2005 | 79 | 0.070 |
Why?
|
Myosin Heavy Chains | 1 | 2006 | 88 | 0.070 |
Why?
|
Chronic Disease | 2 | 2003 | 970 | 0.070 |
Why?
|
Chromosomes, Artificial, Bacterial | 1 | 2005 | 30 | 0.070 |
Why?
|
Patient Identification Systems | 1 | 2005 | 7 | 0.070 |
Why?
|
Collagen | 2 | 1997 | 269 | 0.070 |
Why?
|
Inflammation | 1 | 2011 | 920 | 0.070 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2006 | 90 | 0.070 |
Why?
|
Hyperplasia | 3 | 2013 | 148 | 0.070 |
Why?
|
Staurosporine | 1 | 2005 | 33 | 0.070 |
Why?
|
DNA Primers | 2 | 1997 | 543 | 0.070 |
Why?
|
Data Collection | 1 | 2007 | 372 | 0.070 |
Why?
|
Aspartic Acid | 1 | 2005 | 64 | 0.070 |
Why?
|
Chromosomes, Human, Pair 15 | 2 | 2005 | 63 | 0.070 |
Why?
|
Down-Regulation | 2 | 2022 | 504 | 0.070 |
Why?
|
Hepatitis C | 1 | 2007 | 208 | 0.060 |
Why?
|
Genetic Techniques | 1 | 2005 | 72 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2011 | 1197 | 0.060 |
Why?
|
Eosinophils | 2 | 1997 | 194 | 0.060 |
Why?
|
Paraffin | 2 | 2000 | 4 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 938 | 0.060 |
Why?
|
Chromosomes, Human, Pair 7 | 3 | 2002 | 79 | 0.060 |
Why?
|
Thrombocythemia, Essential | 1 | 2003 | 14 | 0.060 |
Why?
|
Actins | 2 | 1997 | 451 | 0.060 |
Why?
|
Receptors, Cell Surface | 1 | 2005 | 286 | 0.060 |
Why?
|
Case-Control Studies | 4 | 2013 | 1804 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2005 | 2207 | 0.060 |
Why?
|
Risk Factors | 2 | 2012 | 5416 | 0.060 |
Why?
|
Liver | 3 | 2022 | 1229 | 0.060 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2002 | 46 | 0.050 |
Why?
|
Fixatives | 1 | 2002 | 12 | 0.050 |
Why?
|
HIV Seropositivity | 1 | 2002 | 49 | 0.050 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 36 | 0.050 |
Why?
|
Mucin-1 | 2 | 2011 | 44 | 0.050 |
Why?
|
Blotting, Western | 2 | 2001 | 782 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2002 | 64 | 0.050 |
Why?
|
Interleukin-2 | 1 | 2003 | 249 | 0.050 |
Why?
|
Base Sequence | 2 | 1996 | 2330 | 0.050 |
Why?
|
DNA Mismatch Repair | 2 | 2012 | 52 | 0.050 |
Why?
|
Recurrence | 3 | 2002 | 1139 | 0.050 |
Why?
|
Neoplasms, Fibrous Tissue | 1 | 2001 | 2 | 0.050 |
Why?
|
False Negative Reactions | 1 | 2001 | 63 | 0.050 |
Why?
|
Macrophages | 1 | 2005 | 554 | 0.050 |
Why?
|
Vascular Neoplasms | 1 | 2001 | 19 | 0.050 |
Why?
|
Stem Cell Transplantation | 1 | 2003 | 183 | 0.050 |
Why?
|
Laboratories | 1 | 2001 | 43 | 0.050 |
Why?
|
Oncogene Fusion | 1 | 2021 | 8 | 0.050 |
Why?
|
Leukemia, Megakaryoblastic, Acute | 1 | 2001 | 9 | 0.050 |
Why?
|
Receptors, Progesterone | 1 | 2002 | 167 | 0.050 |
Why?
|
Molecular Sequence Data | 2 | 1996 | 3030 | 0.050 |
Why?
|
Cyclophosphamide | 3 | 2011 | 299 | 0.050 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2001 | 51 | 0.050 |
Why?
|
Functional Laterality | 1 | 2002 | 201 | 0.050 |
Why?
|
Piperazines | 1 | 2003 | 272 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2002 | 339 | 0.050 |
Why?
|
Nitriles | 1 | 2021 | 149 | 0.050 |
Why?
|
Exons | 1 | 2023 | 450 | 0.050 |
Why?
|
Reed-Sternberg Cells | 1 | 2000 | 4 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2005 | 589 | 0.050 |
Why?
|
Leiomyosarcoma | 1 | 2001 | 40 | 0.050 |
Why?
|
Pentostatin | 1 | 2020 | 30 | 0.050 |
Why?
|
Receptor, ErbB-2 | 1 | 2002 | 223 | 0.050 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2000 | 24 | 0.050 |
Why?
|
Genes, erbB-2 | 1 | 2000 | 24 | 0.050 |
Why?
|
Gastrointestinal Tract | 1 | 2022 | 191 | 0.050 |
Why?
|
Pyrazoles | 1 | 2021 | 153 | 0.050 |
Why?
|
Receptors, Estrogen | 1 | 2002 | 384 | 0.050 |
Why?
|
Clinical Decision-Making | 1 | 2022 | 257 | 0.050 |
Why?
|
MART-1 Antigen | 1 | 2000 | 19 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2002 | 279 | 0.050 |
Why?
|
Carcinoembryonic Antigen | 1 | 2000 | 41 | 0.050 |
Why?
|
Sjogren's Syndrome | 1 | 2000 | 30 | 0.050 |
Why?
|
Thymus Neoplasms | 1 | 2000 | 41 | 0.050 |
Why?
|
Phospholipase C gamma | 1 | 2019 | 15 | 0.050 |
Why?
|
Viruses | 1 | 2000 | 78 | 0.050 |
Why?
|
Mice, SCID | 1 | 2000 | 252 | 0.050 |
Why?
|
Observer Variation | 1 | 2001 | 602 | 0.050 |
Why?
|
Skin Physiological Phenomena | 1 | 2019 | 27 | 0.040 |
Why?
|
Methotrexate | 1 | 2020 | 249 | 0.040 |
Why?
|
Allografts | 1 | 2020 | 172 | 0.040 |
Why?
|
Cyclosporine | 1 | 2020 | 234 | 0.040 |
Why?
|
Tissue Embedding | 1 | 1999 | 6 | 0.040 |
Why?
|
Guidelines as Topic | 1 | 2020 | 162 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2019 | 34 | 0.040 |
Why?
|
France | 1 | 1999 | 47 | 0.040 |
Why?
|
Regression Analysis | 1 | 2000 | 596 | 0.040 |
Why?
|
Chromosome Banding | 1 | 1999 | 74 | 0.040 |
Why?
|
Cell Line | 2 | 2001 | 2468 | 0.040 |
Why?
|
Organ Transplantation | 1 | 2002 | 265 | 0.040 |
Why?
|
Stem Cells | 1 | 2001 | 351 | 0.040 |
Why?
|
Tacrolimus | 1 | 2020 | 373 | 0.040 |
Why?
|
United Kingdom | 1 | 1999 | 164 | 0.040 |
Why?
|
Mesenchymoma | 1 | 1998 | 4 | 0.040 |
Why?
|
Seminiferous Tubules | 1 | 1998 | 8 | 0.040 |
Why?
|
Methods | 1 | 1998 | 152 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2019 | 116 | 0.040 |
Why?
|
Amino Acid Sequence | 1 | 2002 | 2062 | 0.040 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 1998 | 14 | 0.040 |
Why?
|
Genetic Association Studies | 1 | 2019 | 294 | 0.040 |
Why?
|
Chromogranin A | 1 | 1997 | 8 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 379 | 0.040 |
Why?
|
Kidney Tubules | 1 | 1998 | 94 | 0.040 |
Why?
|
Hemangiosarcoma | 1 | 1997 | 17 | 0.040 |
Why?
|
Classification | 1 | 1998 | 54 | 0.040 |
Why?
|
Serine-Arginine Splicing Factors | 1 | 2017 | 6 | 0.040 |
Why?
|
Coloring Agents | 1 | 1997 | 64 | 0.040 |
Why?
|
CD13 Antigens | 1 | 1997 | 5 | 0.040 |
Why?
|
Sialic Acid Binding Ig-like Lectin 3 | 1 | 1997 | 8 | 0.040 |
Why?
|
Erythrocytes, Abnormal | 1 | 2017 | 12 | 0.040 |
Why?
|
Hamartoma | 1 | 1997 | 31 | 0.040 |
Why?
|
Leiomyoma | 1 | 2001 | 190 | 0.040 |
Why?
|
Bowen's Disease | 1 | 1997 | 9 | 0.040 |
Why?
|
Blood Coagulation Tests | 1 | 2017 | 35 | 0.040 |
Why?
|
Uterine Neoplasms | 1 | 2001 | 226 | 0.040 |
Why?
|
Hemangioma | 1 | 1997 | 60 | 0.040 |
Why?
|
Vulvar Neoplasms | 1 | 1997 | 20 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2017 | 220 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2000 | 1313 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 1997 | 125 | 0.040 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1996 | 65 | 0.040 |
Why?
|
DNA Nucleotidyltransferases | 1 | 1996 | 32 | 0.040 |
Why?
|
DNA, Viral | 1 | 1997 | 265 | 0.040 |
Why?
|
Leukemia, Hairy Cell | 1 | 1997 | 186 | 0.040 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 9 | 0.040 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1996 | 49 | 0.040 |
Why?
|
HLA Antigens | 1 | 1998 | 232 | 0.040 |
Why?
|
Membrane Glycoproteins | 2 | 2002 | 428 | 0.040 |
Why?
|
Iron | 1 | 1997 | 164 | 0.040 |
Why?
|
Breast | 1 | 1998 | 286 | 0.030 |
Why?
|
Gene Fusion | 1 | 2016 | 38 | 0.030 |
Why?
|
Leukocytes | 1 | 2017 | 202 | 0.030 |
Why?
|
Cyclins | 1 | 1996 | 82 | 0.030 |
Why?
|
Cyclin D1 | 1 | 1996 | 83 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 1996 | 59 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 1999 | 1074 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2008 | 2261 | 0.030 |
Why?
|
Hematemesis | 1 | 2015 | 2 | 0.030 |
Why?
|
CD2 Antigens | 1 | 2015 | 22 | 0.030 |
Why?
|
CREB-Binding Protein | 1 | 2015 | 16 | 0.030 |
Why?
|
Diagnostic Tests, Routine | 1 | 2015 | 62 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 36 | 0.030 |
Why?
|
Genetic Testing | 1 | 2019 | 535 | 0.030 |
Why?
|
Disease Management | 1 | 2017 | 327 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2015 | 120 | 0.030 |
Why?
|
Rare Diseases | 1 | 2015 | 59 | 0.030 |
Why?
|
Tumor Cells, Cultured | 3 | 2002 | 1041 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1996 | 291 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2015 | 158 | 0.030 |
Why?
|
Leukocytosis | 1 | 2014 | 16 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 1996 | 468 | 0.030 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2014 | 68 | 0.030 |
Why?
|
Sialic Acid Binding Ig-like Lectin 2 | 1 | 2013 | 5 | 0.030 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 1993 | 4 | 0.030 |
Why?
|
Mucous Membrane | 1 | 1994 | 83 | 0.030 |
Why?
|
Cell Aggregation | 1 | 1993 | 39 | 0.030 |
Why?
|
Paraproteinemias | 1 | 1993 | 13 | 0.030 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1997 | 382 | 0.030 |
Why?
|
Blood Platelets | 1 | 2014 | 149 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2015 | 208 | 0.030 |
Why?
|
Patient Outcome Assessment | 1 | 2014 | 84 | 0.030 |
Why?
|
Lymphocele | 1 | 1992 | 6 | 0.030 |
Why?
|
Phagocytosis | 1 | 2013 | 85 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2013 | 69 | 0.030 |
Why?
|
MutS Homolog 3 Protein | 1 | 2012 | 1 | 0.030 |
Why?
|
Chemoradiotherapy | 1 | 2015 | 301 | 0.030 |
Why?
|
Colon, Sigmoid | 1 | 2012 | 6 | 0.030 |
Why?
|
Chromatin | 1 | 2015 | 380 | 0.030 |
Why?
|
Diploidy | 1 | 1991 | 30 | 0.030 |
Why?
|
Incidence | 2 | 1994 | 1576 | 0.030 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2012 | 48 | 0.030 |
Why?
|
Ohio | 1 | 2011 | 37 | 0.030 |
Why?
|
Electrosurgery | 1 | 2011 | 9 | 0.030 |
Why?
|
Prednisolone | 1 | 2011 | 41 | 0.030 |
Why?
|
Granulomatous Disease, Chronic | 1 | 2011 | 8 | 0.030 |
Why?
|
Vincristine | 1 | 2011 | 111 | 0.030 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2011 | 27 | 0.030 |
Why?
|
Age of Onset | 1 | 2012 | 310 | 0.020 |
Why?
|
Rectum | 1 | 2012 | 146 | 0.020 |
Why?
|
Prostate | 1 | 1994 | 377 | 0.020 |
Why?
|
Delivery, Obstetric | 1 | 2011 | 112 | 0.020 |
Why?
|
Myelopoiesis | 1 | 2010 | 10 | 0.020 |
Why?
|
Urticaria | 1 | 2010 | 10 | 0.020 |
Why?
|
Reference Values | 1 | 1992 | 674 | 0.020 |
Why?
|
Doxorubicin | 1 | 2011 | 295 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 552 | 0.020 |
Why?
|
Ultrasonography, Prenatal | 1 | 2011 | 152 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 481 | 0.020 |
Why?
|
Etoposide | 2 | 2000 | 196 | 0.020 |
Why?
|
Cell Cycle | 1 | 1991 | 502 | 0.020 |
Why?
|
Preleukemia | 1 | 2009 | 10 | 0.020 |
Why?
|
Evaluation Studies as Topic | 2 | 2000 | 274 | 0.020 |
Why?
|
Cell Separation | 1 | 2009 | 196 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 2356 | 0.020 |
Why?
|
Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2008 | 6 | 0.020 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2010 | 159 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2010 | 989 | 0.020 |
Why?
|
Cell Transdifferentiation | 1 | 2008 | 8 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2011 | 937 | 0.020 |
Why?
|
Cryoglobulins | 1 | 2007 | 4 | 0.020 |
Why?
|
Caspases | 1 | 2008 | 155 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2008 | 205 | 0.020 |
Why?
|
Risk Assessment | 1 | 2015 | 2261 | 0.020 |
Why?
|
Time Factors | 1 | 2016 | 5209 | 0.020 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2008 | 156 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2006 | 153 | 0.020 |
Why?
|
Palatine Tonsil | 2 | 1996 | 30 | 0.020 |
Why?
|
Societies, Medical | 1 | 2010 | 572 | 0.020 |
Why?
|
Subcellular Fractions | 1 | 2006 | 93 | 0.020 |
Why?
|
Graft Survival | 2 | 2000 | 884 | 0.020 |
Why?
|
Busulfan | 1 | 2005 | 39 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2005 | 50 | 0.020 |
Why?
|
Pregnancy | 1 | 2011 | 2893 | 0.020 |
Why?
|
Mice | 2 | 2013 | 11352 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2006 | 579 | 0.010 |
Why?
|
Idarubicin | 1 | 2003 | 8 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2009 | 1384 | 0.010 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2003 | 43 | 0.010 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2002 | 13 | 0.010 |
Why?
|
Syndecans | 1 | 2002 | 4 | 0.010 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 2002 | 24 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2005 | 996 | 0.010 |
Why?
|
Syndecan-1 | 1 | 2002 | 13 | 0.010 |
Why?
|
Imatinib Mesylate | 1 | 2003 | 126 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 78 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2003 | 229 | 0.010 |
Why?
|
Phosphorylation | 1 | 2005 | 1106 | 0.010 |
Why?
|
Rituximab | 1 | 2002 | 116 | 0.010 |
Why?
|
Proteoglycans | 1 | 2002 | 121 | 0.010 |
Why?
|
Treatment Failure | 1 | 2002 | 285 | 0.010 |
Why?
|
CD5 Antigens | 1 | 2001 | 14 | 0.010 |
Why?
|
Benzamides | 1 | 2003 | 229 | 0.010 |
Why?
|
Collagen Type IV | 1 | 2001 | 24 | 0.010 |
Why?
|
Histocytochemistry | 1 | 2001 | 130 | 0.010 |
Why?
|
Cerebellar Diseases | 1 | 2000 | 20 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 2000 | 66 | 0.010 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2000 | 14 | 0.010 |
Why?
|
Archives | 1 | 2000 | 3 | 0.010 |
Why?
|
Mice, Inbred NOD | 1 | 2000 | 187 | 0.010 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2000 | 50 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2005 | 2818 | 0.010 |
Why?
|
Receptors, Antigen | 1 | 1999 | 11 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2002 | 427 | 0.010 |
Why?
|
Histocytological Preparation Techniques | 1 | 1999 | 3 | 0.010 |
Why?
|
Fetus | 1 | 2000 | 226 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 3352 | 0.010 |
Why?
|
Antigens | 1 | 2000 | 228 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2000 | 363 | 0.010 |
Why?
|
Serologic Tests | 1 | 1999 | 41 | 0.010 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 1998 | 16 | 0.010 |
Why?
|
Thorax | 1 | 1999 | 75 | 0.010 |
Why?
|
Axilla | 1 | 1999 | 97 | 0.010 |
Why?
|
Surface Properties | 1 | 1998 | 130 | 0.010 |
Why?
|
Sex Chromosome Aberrations | 1 | 1997 | 19 | 0.010 |
Why?
|
Y Chromosome | 1 | 1997 | 28 | 0.010 |
Why?
|
Odds Ratio | 1 | 2000 | 678 | 0.010 |
Why?
|
Radiotherapy | 1 | 2000 | 328 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2000 | 999 | 0.010 |
Why?
|
Sepsis | 1 | 2000 | 306 | 0.010 |
Why?
|
Logistic Models | 1 | 2000 | 1185 | 0.010 |
Why?
|
Tissue Donors | 1 | 1999 | 463 | 0.010 |
Why?
|
Urinary Bladder | 1 | 1997 | 246 | 0.010 |
Why?
|
Prostatectomy | 1 | 1994 | 471 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2000 | 2600 | 0.010 |
Why?
|
Prevalence | 1 | 1994 | 1239 | 0.010 |
Why?
|